Navigation Links
Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD
Date:12/11/2008

ATLANTA, Dec. 11 /PRNewswire/ -- Alimera Sciences Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien(TM) in patients with bilateral geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

The pilot study will compare two doses of Iluvien (0.23 and 0.45 micrograms per day) to sham injection in patients with bilateral geographic atrophy secondary to AMD. The change from baseline in size of geographic atrophy will be assessed over time.

"The impetus for this study was the results of experiments conducted in two animal models of retinal degenerations. In both of these models, a miniaturized version of Iluvien demonstrated protective effects on the spontaneous degeneration which occurs in these animals," said Raymond Iezzi, M.D., M.S., Scientific Director, Ligon Research Center of Vision, Assistant Professor of Ophthalmology, Vitreoretinal Service, Kresge Eye Institute, Wayne State University School of Medicine.

"These results were considered compelling enough to warrant a human study, especially for a condition for which there is no approved treatment," added Dr. Iezzi.

Iluvien, a tiny, intravitreal insert, is currently being studied in the FAME Phase III clinical trial as a way to deliver a very low dose of fluocinolone acetonide, a corticosteroid, to the retina for up to three years as a treatment for diabetic macular edema (DME). An eye care professional, using a proprietary 25-gauge inserter, places Iluvien into the vitreous in a minimally invasive, outpatient procedure.

About Alimera Sciences, Inc.

Alimera Sciences is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently the company is focused on diseases affecting the back of the eye, or retina. Its most advanced product candidate is Iluvien(TM), which is being developed for the treatment of diabetic macular edema, or DME. DME is a disease of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. Under one protocol, enrollment was completed in October 2007 in two Phase 3 pivotal trials for the use of Iluvien in the treatment of DME conducted across the U.S., Canada, Europe and India, with a combined total enrollment of 956 patients.

Alimera also has entered into an exclusive worldwide agreement with Emory University to explore oxidative stress management -- specifically the reduction of reactive oxygen species (ROS) -- as a treatment strategy for ophthalmic diseases. Under this agreement, Alimera has the exclusive option to license compounds, which are nicotinamide adenine dinucleotide phosphate reduced form (NADPH) oxidase inhibitors, as potential treatments for conditions such as the dry form of AMD, particularly the late stage of this condition known as geographic atrophy. Alimera has exercised its option to acquire a license with respect to one of these classes of NADPH oxidase inhibitors.

For more information on Alimera Sciences, visit http://www.alimerasciences.com.


'/>"/>
SOURCE Alimera Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Alimera Sciences, pSivida Limited Amend Medidur(TM) FA Collaboration Agreement
2. Valeant to Acquire Dow Pharmaceutical Sciences, Inc. for $285 Million
3. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
4. YM BIOSCIENCES PROVIDES EU REGULATORY UPDATE
5. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
6. CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East
7. Advanced Life Sciences Announces Cethromycin NDA Accepted for Filing by FDA for the Treatment of Community Acquired Pneumonia
8. DuPont Applied BioSciences Selects MBI to Collaborate on Process Development and Scale-Up for New Bio-based Product
9. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
10. Frost & Sullivan Recognizes Martek Biosciences for Unique and Customer-Focused Strategies With Customer Value Enhancement Award
11. Regado Biosciences to Present at the Piper Jaffray Health Care Conference on Tuesday, December 2, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016  Spherix Incorporated (Nasdaq: ... fostering and monetization of intellectual property, today provided an ... in the Northern District of Texas ... Inter Partes Re-examination ("IPR") proceedings ... Office.  The IPR was initiated on only certain claims ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... of Semantic Graph Database technology has been recognized As “ Best in Semantic ... America Magazine. , “At Corporate America, it’s our priority to showcase prominent professionals ...
(Date:2/4/2016)... (PRWEB) , ... February 04, 2016 , ... Many of ... for over 10 years. What sets them apart from other cuvette manufacturers is ... posted on their website. On top of this steady flow of inside information, ...
(Date:2/3/2016)... Pa. , Feb. 3, 2016  Discovery ... company focused on developing aerosolized KL4 surfactant therapies ... of Directors has approved an inducement award as ... Fraser , its newly appointed President and Chief ... Board,s Compensation Committee on February 1, 2016 and ...
Breaking Biology Technology:
(Date:1/20/2016)... Minn. , Jan. 20, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... 2015. MedNet,s significant achievements are the result of the ... iMedNet eClinical , it,s comprehensive, easy-to-use ... --> --> Key MedNet growth achievements ...
(Date:1/18/2016)... Calif. , Jan. 18, 2016  Extenua ... software that simplifies the use and access of ... and go-to-market partnership with American Cyber.  ... brings extensive experience leading transformational C4ISR and Cyber ... and integrating the latest proven technology solutions," said ...
(Date:1/13/2016)... York , January 13, 2016 ... Research has published a new market report titled - Biometric ... Trends, and Forecast, 2015 - 2023. According to the report, ... 2014 and is anticipated to reach US$1,625.8 mn by ... to 2023. In terms of volume, the biometric sensors ...
Breaking Biology News(10 mins):